Clinical Data ACC 2026: Meta-analysis supports CagriSema as superior first-line therapy in obesity Pharmaceutical TechnologyKOLs note that CagriSema could cannibalise semaglutide's market share in obesity due to its improved weight loss and HbA1c reduction efficacy.Clinical DataMetabolic & GLP-1Read full story pharminent April 2, 2026 (Last updated: April 2, 2026) Pharmaceutical Technology KOLs note that CagriSema could cannibalise semaglutide’s market share in obesity due to its improved weight loss and HbA1c reduction efficacy. Clinical DataMetabolic & GLP-1Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Eli Lilly wins FDA approval for weight loss pill, tees up Novo rivalryNext: AZ claims another win for Imfinzi in frontline liver cancer Related Stories Clinical Data Parsortix study shows promise for ADC target detection pharminent August 3, 2026 Clinical Data Novo setback casts doubt on a new way to treat heart disease pharminent July 31, 2026 Clinical Data Altimmune rises as GLP-1/GIP drug curbs heavy drinking in mid-stage study pharminent July 28, 2026
